CLINICAL TRIAL: MODULATION OF TECHNETIUM-99M MEBROFENIN HEPATIC TRANSPORT TO RIT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这将是一项在男性和女性健康志愿者中进行的开放标签、随机、交叉的临床研究，对象为任何种族的男性和女性，调查单剂量利托那韦(已知的肝脏转运活性调节剂)对氚-99m甲溴芬宁的处置的影响。伽玛发射器的使用将允许实时评估胆汁排泄量、胆囊射血分数和胆汁收集效率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This will be an open-label, randomized, crossover clinical study in male and female healthy volunteers of any ethnicity investigating the effect of a single dose of ritonavir, a known modulator of hepatic transport activity, on the disposition of Technetium Tc-99m mebrofenin. The use of the gamma emitter Technetium Tc-99 mebrofenin will allow real-time assessment of biliary excretion, gallbladder ejection fraction, and the efficiency of bile collection.